Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia

NCT02165397 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02165397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02165397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 3
Overall status
Completed
Start date
July 7, 2014
Completion date
November 7, 2019
Enrollment
181 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

waldenström's macroglobulinemia